YMAB
Price:
$13.82
Market Cap:
$615.95M
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-...[Read more]
Industry
Biotechnology
IPO Date
2018-09-21
Stock Exchange
NASDAQ
Ticker
YMAB
According to Y-mAbs Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -25.13. This represents a change of -18.78% compared to the average of -30.94 of the last 4 quarters.
The mean historical PE Ratio of Y-mAbs Therapeutics, Inc. over the last ten years is -20.17. The current -25.13 PE Ratio has changed 12.36% with respect to the historical average. Over the past ten years (40 quarters), YMAB's PE Ratio was at its highest in in the March 2021 quarter at 9.47. The PE Ratio was at its lowest in in the December 2022 quarter at -132.86.
Average
-20.17
Median
-13.91
Minimum
-46.85
Maximum
-2.21
Discovering the peaks and valleys of Y-mAbs Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 527.43%
Maximum Annual PE Ratio = -2.21
Minimum Annual Increase = -82.18%
Minimum Annual PE Ratio = -46.85
Year | PE Ratio | Change |
---|---|---|
2023 | -13.89 | 527.43% |
2022 | -2.21 | -82.18% |
2021 | -12.42 | -25.98% |
2020 | -16.78 | 20.42% |
2019 | -13.94 | 3.06% |
2018 | -13.52 | -67.57% |
2017 | -41.70 | -10.98% |
The current PE Ratio of Y-mAbs Therapeutics, Inc. (YMAB) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-9.51
5-year avg
-11.85
10-year avg
-20.17
Y-mAbs Therapeutics, Inc.’s PE Ratio is less than TCR2 Therapeutics Inc. (-0.44), less than Revolution Medicines, Inc. (-13.31), less than Black Diamond Therapeutics, Inc. (-3.70), less than Atreca, Inc. (-0.04), less than Passage Bio, Inc. (-0.57), less than bluebird bio, Inc. (-0.52), less than Mersana Therapeutics, Inc. (-1.56), less than Zentalis Pharmaceuticals, Inc. (-1.08), less than Travere Therapeutics, Inc. (-5.83), less than Generation Bio Co. (-0.92), less than Kronos Bio, Inc. (-0.58), less than Erasca, Inc. (-3.94), less than C4 Therapeutics, Inc. (-3.44), less than Edgewise Therapeutics, Inc. (-14.14), less than Arcutis Biotherapeutics, Inc. (-6.44), less than Icosavax, Inc. (-8.27), less than Mirum Pharmaceuticals, Inc. (-18.21), less than VectivBio Holding AG (-7.94), less than Day One Biopharmaceuticals, Inc. (-7.39), greater than Vaxcyte, Inc. (-26.31), less than Larimar Therapeutics, Inc. (-8.80), less than Syndax Pharmaceuticals, Inc. (-6.17), less than Merus N.V. (-18.45), less than Sutro Biopharma, Inc. (-2.69),
Company | PE Ratio | Market cap |
---|---|---|
-0.44 | $58.11M | |
-13.31 | $6.99B | |
-3.70 | $305.13M | |
-0.04 | $3.57M | |
-0.57 | $43.48M | |
-0.52 | $101.94M | |
-1.56 | $165.61M | |
-1.08 | $210.48M | |
-5.83 | $839.88M | |
-0.92 | $145.50M | |
-0.58 | $59.36M | |
-3.94 | $807.96M | |
-3.44 | $374.42M | |
-14.14 | $1.64B | |
-6.44 | $1.21B | |
-8.27 | $769.04M | |
-18.21 | $1.96B | |
-7.94 | $1.06B | |
-7.39 | $1.25B | |
-26.31 | $12.45B | |
-8.80 | $513.64M | |
-6.17 | $1.63B | |
-18.45 | $3.41B | |
-2.69 | $337.69M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Y-mAbs Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Y-mAbs Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Y-mAbs Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Y-mAbs Therapeutics, Inc. (YMAB)?
What is the highest PE Ratio for Y-mAbs Therapeutics, Inc. (YMAB)?
What is the 3-year average PE Ratio for Y-mAbs Therapeutics, Inc. (YMAB)?
What is the 5-year average PE Ratio for Y-mAbs Therapeutics, Inc. (YMAB)?
How does the current PE Ratio for Y-mAbs Therapeutics, Inc. (YMAB) compare to its historical average?